Preoperative CT-based morphological heterogeneity for predicting survival in patients with colorectal cancer liver metastases after surgical resection: a retrospective study

Table 2 Clinical characteristics of patients

	Without MH group (n = 78)	With MH group (n = 24)	χ²/Z	p-value
Age(year)	56.2 ± 11.2	56.0 ± 10.5	-0.241	0.810
Gender
Male Female	47	16	0.319	0.572
Male Female	31	8	0.319	0.572
Time of diagnosing CRLM
Synchronous Metachronous	60	22	1.682	0.195
Synchronous Metachronous	18	2	1.682	0.195
Number of liver lesions (median)	2.0 (2.0, 3.35)	5.0 (4.0, 6.0)	-5.594	*<0.001*
length of largest liver lesions (median) (mm)	26 (20, 40.5)	26 (21, 31)	-0.794	0.427
Primary tumor site
Colon Rectum	55	15	0.547	0.459
Colon Rectum	23	9	0.547	0.459
T-stage of primary tumor
1–2 3–4	9	0	1.665	0.197
1–2 3–4	69	23	1.665	0.197
N-stage of primary tumor
0–1 2	58	20	1.603	0.205
0–1 2	20	3	1.603	0.205
Genetic mutation
No Yes	40	20	5.181	*0.023*
No Yes	21	2	5.181	*0.023*
Treatment before surgery
Chemotherapy With target therapy	38	9	0.930	0.335
Chemotherapy With target therapy	40	15	0.930	0.335
Use RFA in surgery
No Yes	69	21	0.000	1.000
No Yes	9	3	0.000	1.000
Chemotherapy after surgery
No Yes	14	2	0.552	0.457
No Yes	64	21	0.552	0.457
With extrahepatic matastasis
Yes No	13	0	3.208	0.073
Yes No	65	24
Preoperative CEA (ng/ml)	11.90 (3.82, 44.11)	12.60 (4.18, 23.18)	-0.165	0.869

T-stage tumor-stage, N-stage node stage, RFA radiofrequency ablation, CEA carcinoembryonic antigen
Note: The clinical data of the patients were not comprehensive. There were one case unclear with primary T-stage, one case unclear with N-stage, one case unclear with postoperative chemotherapy, and 19 cases unclear with gene mutation

ISSN: 1471-2342